For patients with metastatic prostate cancer, understanding its genesis and evolution can mean all the difference for treatment. But, what if, as a recent Journal of Nuclear Medicine perspective proposes, a new clinical state could improve understanding and treatment of the disease?
Hossein Jadvar, MD, PhD, with the University of Southern California in Los Angeles examined what previous researchers termed the oligometastatic state. The term is used to describe a step in metastatic cancer progression between the localized confined process to a disseminated state, according to the July 20 article.
The postulate here is that oligometastatic lesions are early along their evolutionary line of metastatic potentiation, he wrote. The management implication then follows that in some patients with oligometastases, cure may still be possible with definitive metastasisdirected therapies (MDTs) and minimal systemic toxic effects.
Currently, imaging plays a pivotal role in the acceptance of this state, Jadvar wrote. Techniques such as stereotactic body radiation therapy-(SBRT) and local ablation have increased clinical interest in oligometastic disease. However, evidence for taking this treatment approach is lacking, and few studies have done much to prove otherwise.